(±)-Taxifolin (Synonyms: (±)-Dihydroquercetin)

Name: (±)-Taxifolin
Brand: MedChemExpress
SKU: HY-N0136A
Rating: 4.5 (1 reviews)

Cat. No.: HY-N0136A Purity: 99.34%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

(±)-Taxifolin ((±)-Dihydroquercetin) is the racemate of Taxifolin. Taxifolin exhibits important anti-tyrosinase activity. Taxifolin exhibits significant inhibitory activity against collagenase with an IC₅₀ value of 193.3 μM. Taxifolin is an important natural compound with antifibrotic activity. Taxifolin is a free radical scavenger with antioxidant capacity.

For research use only. We do not sell to patients.

(±)-Taxifolin Chemical Structure

CAS No. : 24198-97-8

Size	Price	Stock	Quantity
50 mg	USD 65	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 110	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of (±)-Taxifolin:

Taxifolin In-stock
(-)-Taxifolin Get quote
(±)-Taxifolin-¹³C₃ Get quote

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

(±)-Taxifolin ((±)-Dihydroquercetin) is the racemate of Taxifolin. Taxifolin exhibits important anti-tyrosinase activity. Taxifolin exhibits significant inhibitory activity against collagenase with an IC₅₀ value of 193.3 μM^[1]. Taxifolin is an important natural compound with antifibrotic activity. Taxifolin is a free radical scavenger with antioxidant capacity^[2].

Cellular Effect

Cell Line	Type	Value	Description	References
BJ	EC₅₀	> 10 μM Compound: 1	Cytotoxicity against human BJ cells assessed as viable cells after 72 hrs by calcein AM assay Cytotoxicity against human BJ cells assessed as viable cells after 72 hrs by calcein AM assay	[PMID: 20192247]
CCRF-CEM	EC₅₀	> 10 μM Compound: 1	Cytotoxicity against human CEM cells assessed as viable cells after 72 hrs by calcein AM assay Cytotoxicity against human CEM cells assessed as viable cells after 72 hrs by calcein AM assay	[PMID: 20192247]
HEK293	EC₅₀	670.66 μM Compound: DHQ	Cytotoxicity in HEK293 cells assessed as reduction in cell survival incubated for 48 hrs by MTT assay Cytotoxicity in HEK293 cells assessed as reduction in cell survival incubated for 48 hrs by MTT assay	[PMID: 30108751]
HeLa	EC₅₀	> 10 μM Compound: 1	Cytotoxicity against human HeLa cells assessed as viable cells after 72 hrs by calcein AM assay Cytotoxicity against human HeLa cells assessed as viable cells after 72 hrs by calcein AM assay	[PMID: 20192247]
HeLa	EC₅₀	125.31 μM Compound: DHQ	Cytotoxicity in human HeLa cells assessed as reduction in cell survival incubated for 48 hrs by MTT assay Cytotoxicity in human HeLa cells assessed as reduction in cell survival incubated for 48 hrs by MTT assay	[PMID: 30108751]
HL-60	IC₅₀	10 ng/mL Compound: Taxifolin	Growth inhibition of human HL60 cells after 72 hrs by MTT assay Growth inhibition of human HL60 cells after 72 hrs by MTT assay	[PMID: 31398616]
L929	EC₅₀	200 μM Compound: taxifolin	Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by crystal violet staining Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by crystal violet staining	[PMID: 9287415]
L929	EC₅₀	240 μM Compound: taxifolin	Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by [methyl-3H]thymidine incorporation assay Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by [methyl-3H]thymidine incorporation assay	[PMID: 9287415]
MCF7	EC₅₀	> 10 μM Compound: 1	Cytotoxicity against human MCF7 cells assessed as viable cells after 72 hrs by calcein AM assay Cytotoxicity against human MCF7 cells assessed as viable cells after 72 hrs by calcein AM assay	[PMID: 20192247]
MT4	IC₅₀	> 25.4 μg/mL Compound: 14	Antiviral activity against HIV infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 10425115]
MT4	CC₅₀	25.4 μg/mL Compound: 14	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 10425115]
Neutrophil	IC₅₀	15.3 μM Compound: 5c	Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of HOCl-induced oxidation of APF after 6 mins by fluorescence assay Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of HOCl-induced oxidation of APF after 6 mins by fluorescence assay	[PMID: 23871908]
Neutrophil	IC₅₀	15.5 μM Compound: 5c	Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of superoxide anion radical-induced lucigenin oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of superoxide anion radical-induced lucigenin oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay	[PMID: 23871908]
Neutrophil	IC₅₀	41.3 μM Compound: 5c	Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of H2O2-induced oxidation of amplex red incubated for 5 mins prior to PMA challenge by fluorescence assay Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of H2O2-induced oxidation of amplex red incubated for 5 mins prior to PMA challenge by fluorescence assay	[PMID: 23871908]
Neutrophil	IC₅₀	53.5 μM Compound: 5c	Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of ROS-induced luminol oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of ROS-induced luminol oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay	[PMID: 23871908]
RAW264.7	IC₅₀	81.6 μM Compound: 10	Inhibition of LPS-induced NO production in mouse RAW264.7 cells by Griess reagent based assay Inhibition of LPS-induced NO production in mouse RAW264.7 cells by Griess reagent based assay	[PMID: 32118424]
RPMI-8226	EC₅₀	> 10 μM Compound: 1	Cytotoxicity against human RPMI8226 cells assessed as viable cells after 72 hrs by calcein AM assay Cytotoxicity against human RPMI8226 cells assessed as viable cells after 72 hrs by calcein AM assay	[PMID: 20192247]
Sf9	IC₅₀	15.7 μM Compound: 4	Inhibition of N-terminal GST-His-tagged c-KIT (544 to 976 amino acids) D816V mutant (unknown origin) expressed in Sf9 insect cells using poly[Glu:Tyr] (4:1) as substrate preincubated for 20 mins followed by [33P-gamma]ATP addition and subsequent inhibitio Inhibition of N-terminal GST-His-tagged c-KIT (544 to 976 amino acids) D816V mutant (unknown origin) expressed in Sf9 insect cells using poly[Glu:Tyr] (4:1) as substrate preincubated for 20 mins followed by [33P-gamma]ATP addition and subsequent inhibitio	[PMID: 26807861]
THP-1	EC₅₀	> 10 μM Compound: 1	Cytotoxicity against human THP1 cells after 72 hrs by erythosin B staining method Cytotoxicity against human THP1 cells after 72 hrs by erythosin B staining method	[PMID: 20192247]
U-266	EC₅₀	> 10 μM Compound: 1	Cytotoxicity against human U266 cells assessed as viable cells after 72 hrs by calcein AM assay Cytotoxicity against human U266 cells assessed as viable cells after 72 hrs by calcein AM assay	[PMID: 20192247]

Molecular Weight

304.25

Formula

C₁₅H₁₂O₇

CAS No.

24198-97-8

Appearance

Solid

Color

White to off-white

SMILES

O=C1[C@H](O)[C@@H](C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C13

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (328.68 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.2868 mL	16.4339 mL	32.8677 mL
5 mM	0.6574 mL	3.2868 mL	6.5735 mL
10 mM	0.3287 mL	1.6434 mL	3.2868 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.22 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.22 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (8.22 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.34%

Select Batch:

Data Sheet (279 KB) SDS (392 KB)

COA (257 KB) HNMR (269 KB) LCMS (94 KB) Elemental Analysis Report (115 KB)

Handling Instructions (2659 KB)

References

[1]. Angelis A, et al. Bio-Guided Isolation of Methanol-Soluble Metabolites of Common Spruce (Picea abies) Bark by-Products and Investigation of Their Dermo-Cosmetic Properties. Molecules. 2016 Nov 21;21(11):1586. [Content Brief]

[2]. Lei Ren, et al. Dissecting Efficacy and Metabolic Characteristic Mechanism of Taxifolin on Renal Fibrosis by Multivariate Approach and Ultra-Performance Liquid Chromatography Coupled With Mass Spectrometry-Based Metabolomics Strategy. Front Pharmacol. 202 [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.2868 mL	16.4339 mL	32.8677 mL	82.1693 mL
	5 mM	0.6574 mL	3.2868 mL	6.5735 mL	16.4339 mL
	10 mM	0.3287 mL	1.6434 mL	3.2868 mL	8.2169 mL
	15 mM	0.2191 mL	1.0956 mL	2.1912 mL	5.4780 mL
	20 mM	0.1643 mL	0.8217 mL	1.6434 mL	4.1085 mL
	25 mM	0.1315 mL	0.6574 mL	1.3147 mL	3.2868 mL
	30 mM	0.1096 mL	0.5478 mL	1.0956 mL	2.7390 mL
	40 mM	0.0822 mL	0.4108 mL	0.8217 mL	2.0542 mL
	50 mM	0.0657 mL	0.3287 mL	0.6574 mL	1.6434 mL
	60 mM	0.0548 mL	0.2739 mL	0.5478 mL	1.3695 mL
	80 mM	0.0411 mL	0.2054 mL	0.4108 mL	1.0271 mL
	100 mM	0.0329 mL	0.1643 mL	0.3287 mL	0.8217 mL

(±)-Taxifolin Related Classifications

Inflammation/Immunology

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

(±)-Taxifolin24198-97-8(±)-DihydroquercetinAutophagyTyrosinaseantifibroticantioxidantInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Salutation
Applicant Name *			Email Address *
Phone Number *			Organization Name *
Department *			Requested quantity *
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

(±)-Taxifolin (Synonyms: (±)-Dihydroquercetin)

Customer Review

Other Forms of (±)-Taxifolin:

(±)-Taxifolin Related Antibodies

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Purity & Documentation

References

Customer Review

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

(±)-Taxifolin Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report